MedTech Atlas
Back to medical device regulatory guideAll countries
Asia PacificENPublic regulatory overview

Thailand

Country Overview Market Notes: Thailand requires a locally licensed importer/license holder to serve as the registration applicant and import license holder. Local execution qualit...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingSupportive evidence

NMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Thailand
  • Product line: Medical devices
  • Regulator / source: Regulatory Authority
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
  • Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
  • Local requirement: Market Notes: Thailand requires a locally licensed importer/license holder to serve as the registration applicant and import license holder. Local execution quality, Thai-language labeling, and dossier compliance with TFDA (Thai FDA) format requirements are critical success factors for market entry.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Country Overview

  • Market Notes: Thailand requires a locally licensed importer/license holder to serve as the registration applicant and import license holder. Local execution quality, Thai-language labeling, and dossier compliance with TFDA (Thai FDA) format requirements are critical success factors for market entry.

Regulatory Authority

  • Primary Authority: Thai FDA (Food and Drug Administration, Thailand — อย.); operates under the Ministry of Public Health
  • Legal Framework: Medical Device Act B.E. 2562 (2019) and associated notifications and guidelines

Device Classification System

Local Class Risk Level Approximate EU Equivalent Notes
Class 1 Low Class I Lowest risk; simplified registration
Class 2 Low-Moderate Class IIa Standard registration; moderate documentation required
Class 3 Moderate-High Class IIb Full technical review required
Class 4 High Class III Most stringent; full clinical evidence requirements

Official Sources and Verification Date

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.